These may be used as glucose transporter type 4 (GLUT4) membrane transfer agonists and GLUT4 protein expression agonists, and therefore can be used in the therapy of diabetes and its complications (wherein R1, R2, R5, and R6 = H, alkyl, alkenyl, or phenyl groups; R3 and R4 = H, alkyl, alkenyl, Ph, hydroxy, or alkoxy groups). This evidence concerns the gene SLC2A4 and diabetes mellitus.